Ferozsons Laboratories Reports 22% Profit Growth in FY25

Karachi, September 23, 2025 –

Ferozsons Laboratories Limited (PSX: FEROZ) announced its consolidated financial results for the fiscal year ended June 30, 2025, showcasing strong growth across revenue and profitability metrics.

The company’s profit after tax (PAT) surged by 22% to Rs921.71 million, up from Rs755.4m in FY24. Earnings per share (EPS) rose to Rs17.86, compared to Rs15.72 last year, reflecting a healthy 13.6% increase.

On the top line, net revenue climbed 18.9% year-on-year, reaching Rs18.86 billion versus Rs15.85bn in FY24. This growth was supported by strong product demand, although it was partly offset by rising costs.

• Cost of sales rose by 15.6% YoY to Rs10.86bn, leading to a gross profit of Rs7.99bn, up 23.7% from last year’s Rs6.46bn.
• Operating expenses increased, with administrative expenses up 6.7% to Rs901.83m, and selling & distribution expenses surging 30.8% to Rs4.95bn.
• Other expenses registered an 8.6% rise to Rs267.46m, while other income provided some relief, growing 11.4% to Rs254.94m.

As a result, profit from operations improved 17.5%, standing at Rs2.13bn, compared to Rs1.82bn in the prior year.

The company also benefited from lower borrowing costs, as finance costs fell 14.6% to Rs574.28m, down from Rs672.45m in FY24. Consequently, profit before tax reached Rs1.56bn, reflecting a 36.4% increase.

After accounting for higher taxation—up 72% to Rs603.48m—Ferozsons concluded FY25 with a net profit of Rs921.71m, consolidating its position as a strong performer in the pharmaceutical sector despite expense pressures.